HRP20040510A2 - Amorphous and crystalline forms of losartan potassium and process for their preparation - Google Patents

Amorphous and crystalline forms of losartan potassium and process for their preparation

Info

Publication number
HRP20040510A2
HRP20040510A2 HR20040510A HRP20040510A HRP20040510A2 HR P20040510 A2 HRP20040510 A2 HR P20040510A2 HR 20040510 A HR20040510 A HR 20040510A HR P20040510 A HRP20040510 A HR P20040510A HR P20040510 A2 HRP20040510 A2 HR P20040510A2
Authority
HR
Croatia
Prior art keywords
amorphous
preparation
crystalline forms
losartan potassium
losartan
Prior art date
Application number
HR20040510A
Other languages
English (en)
Inventor
Dolitzky Ben-Zion
Nisnevich Gennady
Wizel Shlomit
Kaftanov Julia
Rukhman Igor
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HRP20040510A2 publication Critical patent/HRP20040510A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
HR20040510A 2001-11-14 2004-06-07 Amorphous and crystalline forms of losartan potassium and process for their preparation HRP20040510A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33303401P 2001-11-14 2001-11-14
US40127802P 2002-08-05 2002-08-05
PCT/US2002/036550 WO2003048135A1 (fr) 2001-11-14 2002-11-13 Formes cristallines amorphes de losartan potassique et leur procede de preparation

Publications (1)

Publication Number Publication Date
HRP20040510A2 true HRP20040510A2 (en) 2005-08-31

Family

ID=26988524

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040510A HRP20040510A2 (en) 2001-11-14 2004-06-07 Amorphous and crystalline forms of losartan potassium and process for their preparation

Country Status (16)

Country Link
US (2) US7332612B2 (fr)
EP (1) EP1458693A4 (fr)
JP (2) JP2006504618A (fr)
KR (1) KR20050044450A (fr)
CN (1) CN1612866A (fr)
AU (1) AU2002360386A1 (fr)
CA (2) CA2465597A1 (fr)
ES (1) ES2234451T1 (fr)
HR (1) HRP20040510A2 (fr)
HU (1) HUP0501067A2 (fr)
IL (1) IL161970A0 (fr)
IS (1) IS7262A (fr)
MX (1) MXPA04004657A (fr)
NO (1) NO20042434L (fr)
PL (1) PL374442A1 (fr)
WO (1) WO2003048135A1 (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227742B1 (en) 1996-10-18 2012-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
WO2004035049A1 (fr) * 2002-10-17 2004-04-29 Teva Pharmaceutical Industries Ltd. Procede pour preparer du potassium de losartan avec coulabilite amelioree
WO2004039352A2 (fr) * 2002-10-31 2004-05-13 Ranbaxy Laboratories Limited Forme amorphe de losartan potassium
IL154370A0 (en) * 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
ITMI20030328A1 (it) * 2003-02-25 2004-08-26 Dinamite Dipharma S P A In Forma A Bbreviata Diph Polimorfi di losartan potassio e procedimento per la loro preparazione.
WO2004076443A1 (fr) * 2003-02-25 2004-09-10 Hetero Drugs Limited Forme amorphe de potassium de losartan
WO2004076442A1 (fr) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Polymorphes de losartan
US7345071B2 (en) 2003-05-07 2008-03-18 Ipca Laboratories Limited Process for the synthesis of Losartan potassium
UY28500A1 (es) 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
ITMI20032472A1 (it) * 2003-12-16 2005-06-17 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procedimento per la preparazione di losartan potassio cristallino
EP1709034A2 (fr) * 2004-01-06 2006-10-11 IPCA Laboratories Limited Procede ameliore de synthese du losartan potassique
EP1713795A2 (fr) 2004-02-11 2006-10-25 Teva Pharmaceutical Industries Ltd. Polymorphes de candesartan cilexetil
US20080242725A1 (en) * 2004-03-01 2008-10-02 Janez Kerc Pharmaceutical Composition
EP1729766A1 (fr) * 2004-03-01 2006-12-13 LEK Pharmaceuticals D.D. Formulation pharmaceutique
WO2005111021A1 (fr) * 2004-05-05 2005-11-24 Teva Pharmaceutical Industries Ltd. Elaboration de of candesartan cilexetil de purete elevee
AU2005253957B2 (en) * 2004-06-08 2011-08-25 Janssen Pharmaceutica Nv Pharmaceutical compositions
IL171137A (en) 2004-09-29 2012-01-31 Chemagis Ltd Use of purified malt donfazil for the preparation of pure pharmaceutical amorphous donfazil hydrochloride
US20060160871A1 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
US20090076281A1 (en) * 2005-05-05 2009-03-19 Medichem, S.A. Process for the preparation of losartan and its salts
CN101277950B (zh) * 2005-08-02 2013-03-27 弗特克斯药品有限公司 丝氨酸蛋白酶抑制剂
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US20090304755A1 (en) * 2005-10-27 2009-12-10 Raghu Rami Reddy Kasu Pharmaceutical formulation of losartan
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
EP1991229A2 (fr) 2006-02-27 2008-11-19 Vertex Pharmaceuticals Incorporated Co-cristaux et compositions pharmaceutiques les comprenant
MX2008011868A (es) 2006-03-16 2008-12-15 Vertex Pharma Inhibidores deuterados de la proteasa de la hepatitis c.
EP2463285A1 (fr) * 2007-02-27 2012-06-13 Vertex Pharmaceuticals Inc. Co-cristaux et compositions pharmaceutiques les comprenant
CA2679426A1 (fr) * 2007-02-27 2008-09-04 Luc Farmer Inhibiteurs de serine proteases
MX2010002407A (es) * 2007-08-30 2010-03-26 Vertex Pharma Cocristales y composiciones farmaceuticas que los comprenden.
CA2733908C (fr) 2008-08-13 2017-05-30 Vertex Pharmaceuticals Incorporated Composition pharmaceutique renfermant une dispersion solide de n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoqsinolin e-3-carboxamide
MA33056B1 (fr) 2009-01-23 2012-02-01 Hanmi Holding Co Ltd Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication
EP2490687A1 (fr) 2009-10-22 2012-08-29 Vertex Pharmaceuticals Incorporated Compositions destinées au traitement de la mucoviscidose et d'autres maladies chroniques
WO2011133951A1 (fr) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques et leurs administrations
CA2796602A1 (fr) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques et leurs administrations
NZ603044A (en) 2010-04-22 2015-08-28 Vertex Pharma Pharmaceutical compositions comprising cftr modulators and administrations thereof
CA2798412A1 (fr) 2010-05-20 2011-11-24 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques et leurs administrations
MX2013002353A (es) 2010-08-27 2013-09-26 Vertex Pharma Composicion farmaceutica y administraciones de la misma.
CA2853299A1 (fr) 2011-11-02 2013-05-10 Vertex Pharmaceuticals Incorporated (n-[2,4-bis(1,1-dimethylethyle)-5-hydroxyphenyle]-1,4-dihydro-4-oxoquinoline-3-carboxamide) pour traiter des maladies mediees par cftr
EP2819670A1 (fr) 2012-02-27 2015-01-07 Vertex Pharmaceuticals Incorporated Composition pharmaceutique et son administration
AU2013270681A1 (en) 2012-06-08 2014-12-18 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of CFTR -mediated disorders
AU2013277429B2 (en) 2012-06-19 2016-01-14 Intercept Pharmaceuticals, Inc. Preparation, uses and solid forms of obeticholic acid
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
MX2021001169A (es) 2013-11-15 2023-02-10 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.
US10206877B2 (en) 2014-04-15 2019-02-19 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
TWI735416B (zh) 2014-10-06 2021-08-11 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
MA54847A (fr) 2016-12-09 2021-12-08 Vertex Pharma Forme crystalline d'un n-(pyrazol-4-yl)sulfonyl-6-(pyrazol-1-yl)-2-(pyrrolidin-1-yl)pyridine-3-carboxamide pour traiter la mucoviscidose
US20180280349A1 (en) 2017-03-28 2018-10-04 Vertex Pharmaceuticals Incorporated Methods of treating cystic fibrosis in patients with residual function mutations
EP3634402A1 (fr) 2017-06-08 2020-04-15 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la fibrose kystique
US20210069174A1 (en) 2017-07-01 2021-03-11 Vertex Pharmaceuticals Incorporated Compositions and methods for treatment of cystic fibrosis
WO2019018395A1 (fr) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la fibrose kystique
AU2018351533B2 (en) 2017-10-19 2023-02-02 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
US20210228489A1 (en) 2017-12-04 2021-07-29 Vertex Pharmaceuticals Incorporated Compositions for treating cystic fibrosis
KR20200097293A (ko) 2017-12-08 2020-08-18 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
CN112004817B (zh) 2018-02-15 2023-06-23 弗特克斯药品有限公司 作为cftr的调节剂的大环化合物、其药物组合物、它们的用途和制备方法
US20210009560A1 (en) 2018-03-30 2021-01-14 Vertex Pharmaceuticals Incorporated Crystalline forms of modulators of cftr
BR112021006392A2 (pt) 2018-10-05 2021-07-06 Vertex Pharma moduladores da alfa-1 antitripsina
LT3880197T (lt) 2018-11-14 2023-05-10 Vertex Pharmaceuticals Incorporated Cistinės fibrozės gydymo būdai
BR112021011564A2 (pt) 2018-12-17 2021-08-31 Vertex Pharmaceuticals Incorporated Inibidores de apol1 e métodos de uso dos mesmos
AR118555A1 (es) 2019-04-03 2021-10-20 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2020214921A1 (fr) 2019-04-17 2020-10-22 Vertex Pharmaceuticals Incorporated Formes solides de modulateurs de cftr
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
WO2020242935A1 (fr) 2019-05-29 2020-12-03 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la mucoviscidose
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
CN114599657A (zh) 2019-08-14 2022-06-07 弗特克斯药品有限公司 Cftr调节剂的结晶形式
JP2023507125A (ja) 2019-12-20 2023-02-21 プリンシピア バイオファーマ インコーポレイテッド ２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペント－２－エンニトリルの固体形態
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
IL300413A (en) 2020-08-13 2023-04-01 Vertex Pharma Crystal forms of CFTR modulators
US20240002386A1 (en) 2020-11-17 2024-01-04 Vertex Pharmaceuticals Incorporated Solid forms of 4-(5-(4-fluorophenyl)-6-(tetrahydro-2h-pyran-4-yl)-1,5-dihydropyrrolo[2,3-f]indazol-7-yl)benzoic acid
MX2023006770A (es) 2020-12-10 2023-08-14 Vertex Pharma Metodos de tratamiento para fibrosis quistica.
WO2022256702A1 (fr) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Tétrahydrofuran-2-carboxamides substitués utiles en tant que modulateurs de canaux sodiques
CA3221960A1 (fr) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Tetrahydrofuranes a substitution hydroxy et (halo)alkoxy utiles en tant que modulateurs de canaux sodiques
PE20241335A1 (es) 2021-06-04 2024-07-03 Vertex Pharma N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
WO2022256676A1 (fr) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Analogues de tétrahydrofurane substitués utiles en tant que modulateurs de canaux sodiques
WO2022256679A1 (fr) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Analogues de n-(hydroxyalkyl(hétéro)aryl)tétrahydrofurane carboxamide en tant que modulateurs de canaux sodiques
AU2023215372A1 (en) 2022-02-03 2024-08-22 Vertex Pharmaceuticals Incorporated Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol
WO2023224924A1 (fr) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Formes solides de composés macrocycliques en tant que modulateurs de cftr et leur préparation
WO2023244562A1 (fr) 2022-06-14 2023-12-21 Principia Biopharma Inc. Formes cristallines de 2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidin-1- yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétan-3-yl)pipérazin-1-yl]pent-2-enenitrile
WO2024031081A1 (fr) 2022-08-04 2024-02-08 Vertex Pharmaceuticals Incorporated Compositions pour le traitement de maladies médiées par cftr
TW202421121A (zh) 2022-09-09 2024-06-01 美商維泰克斯製藥公司 α-１抗胰蛋白酶之調節劑

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5140037A (en) * 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists
US5130439A (en) * 1991-11-18 1992-07-14 Lo Young S Tetrazolylphenylboronic acid intermediates for the synthesis of AII receptor antagonists
US5206374A (en) * 1991-11-18 1993-04-27 E. I. Du Pont De Nemours And Company Process for preparing tetrazolylphenylboronic acid intermediates
US5310928A (en) * 1991-11-18 1994-05-10 E. I. Du Pont De Nemours And Company Process for preparing biphenyltetrazole compounds
JP3266395B2 (ja) * 1993-11-24 2002-03-18 富士写真フイルム株式会社 有機薬品の晶析方法
JPH09507075A (ja) * 1993-12-23 1997-07-15 メルク エンド カンパニー インコーポレーテッド ロサルタンの多形とロサルタン▲ｉｉ▼形調製のための方法
JP3883205B2 (ja) * 1994-03-29 2007-02-21 メルク エンド カンパニー インコーポレーテッド アンギオテンシン▲ｉｉ▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療
GB9406573D0 (en) * 1994-03-31 1994-05-25 Merck Sharp & Dohme Medicaments
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
JPH1085502A (ja) * 1996-09-19 1998-04-07 Konica Corp 晶析方法

Also Published As

Publication number Publication date
IL161970A0 (en) 2005-11-20
KR20050044450A (ko) 2005-05-12
JP2006504618A (ja) 2006-02-09
US7332612B2 (en) 2008-02-19
CA2465597A1 (fr) 2003-06-12
ES2234451T1 (es) 2005-07-01
EP1458693A1 (fr) 2004-09-22
IS7262A (is) 2004-05-13
MXPA04004657A (es) 2004-08-13
EP1458693A4 (fr) 2005-02-09
US20080096945A1 (en) 2008-04-24
AU2002360386A1 (en) 2003-06-17
CN1612866A (zh) 2005-05-04
JP2009173685A (ja) 2009-08-06
NO20042434L (no) 2004-06-11
HUP0501067A2 (en) 2006-02-28
CA2672549A1 (fr) 2003-06-12
US20040006237A1 (en) 2004-01-08
WO2003048135A1 (fr) 2003-06-12
PL374442A1 (en) 2005-10-17

Similar Documents

Publication Publication Date Title
HRP20040510A2 (en) Amorphous and crystalline forms of losartan potassium and process for their preparation
EP1425279A4 (fr) Procede de preparation de tetrahydrobenzothiepines cristallines
WO2005062897A3 (fr) Formes polymorphes d'ezetimibe et procedes de preparation de celles-ci
AU2003238664A1 (en) Polymorphs and amorphous form of (s) - (+) -clopidogrel bisulfate
HUP0300875A3 (en) Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
HRP20040077A2 (en) Crystalline forms vi and vii of atorvastatin-calcium
PL368984A1 (en) Process for the preparation of crystalline imipenem
EP1534727A4 (fr) Formes cristallines et amorphes de beta-l-2'-deoxythymidine
EP1430054A4 (fr) Purification et des formes cristallines de zaleplon
AU2001288092A1 (en) Method of crystallization
IL166592A0 (en) Novel crystalline forms of gatifloxacin
AU2003260078A8 (en) Crystalline and amorphous forms of (s) -repaglinide and the processes for preparation thereof
IL165115A0 (en) Novel crystalline forms of gatifloxacin
EP1547993A4 (fr) Procede de preparation de spirofluorenols
AU2001289303A1 (en) Process for producing crystalline tagatose
HUP0103702A3 (en) Polymorphic crystalline forms of 1-pyrrole derivatives and process for their preparation
AU2003262928A8 (en) Crystalline form of nateglinide and process for preparation thereof
AU2003250086A1 (en) Crystalline polymorphic and amorphous forms of benazepril hydrochloride
AU2003209669A1 (en) Amorphous form of losartan potassium
AU2002356423A1 (en) Process for the preparation of amorphous atorvastatin calcium
AU2003217438A1 (en) Novel crystalline forms of levetiracetam
AU2003278422A8 (en) Amorphous form of losartan potassium
AU2003300874A1 (en) Crystalline forms of gatifloxacin and processes for preparation
AU2001245429A1 (en) Process for preparing pure crystalline lorazepam
IL165690A0 (en) Novel crystalline forms of gatifloxacin

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20071109

Year of fee payment: 6

OBST Application withdrawn